30-Mar-2026
Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award
Globe Newswire (Thu, 12-Mar 8:00 AM ET)
Globe Newswire (Mon, 9-Mar 4:05 PM ET)
Ardelyx to Participate in Upcoming Investor Conferences
Globe Newswire (Wed, 4-Mar 8:00 AM ET)
Globe Newswire (Tue, 24-Feb 8:00 AM ET)
ARDX's IBSRELA Delivers 73% Revenue Growth in 2025 as Company Eyes Billion-Dollar Milestone
Market Chameleon (Fri, 20-Feb 2:06 AM ET)
Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Globe Newswire (Thu, 19-Feb 4:01 PM ET)
Market Chameleon (Thu, 5-Feb 3:43 AM ET)
Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026
Globe Newswire (Thu, 5-Feb 8:00 AM ET)
Ardelyx Receives New Patent for Tenapanor
Globe Newswire (Tue, 3-Feb 8:29 AM ET)
First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA
Globe Newswire (Wed, 28-Jan 8:29 AM ET)
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Ardelyx trades on the NASDAQ stock market under the symbol ARDX.
As of March 30, 2026, ARDX stock price climbed to $5.55 with 2,426,754 million shares trading.
ARDX has a beta of 0.94, meaning it tends to be less sensitive to market movements. ARDX has a correlation of 0.06 to the broad based SPY ETF.
ARDX has a market cap of $1.36 billion. This is considered a Small Cap stock.
Last quarter Ardelyx reported $125 million in Revenue and $.00 earnings per share. This beat revenue expectation by $7 million and missed earnings estimates by -$.01.
In the last 3 years, ARDX traded as high as $10.13 and as low as $3.16.
The top ETF exchange traded funds that ARDX belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.
ARDX has underperformed the market in the last year with a return of +8.0%, while SPY returned +12.7%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in ARDX shares. However, ARDX has outperformed the market in the last 3 month and 2 week periods, returning -3.3% and -4.0%, while SPY returned -8.2% and -4.3%, respectively. This indicates ARDX has been having a stronger performance recently.
ARDX support price is $5.29 and resistance is $5.67 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ARDX shares will trade within this expected range on the day.